RE: Nice RAH summary19 Sep 2023 13:45
A nice summary by RAH of key points from the announcement but I would take issue with one thing that was written, namely:
"At 310mg of Dox (sic [AVA6000]), 209mg of AVA6000 (sic [doxorubicin]) equivalent (but targeted and therefore super charged) AVA6000 continues to be received safely."
We cannot assume that 310mg/m² of AVA6000 is equivalent to 209mg/m² of straight doxorubicin, only that 209mg/m² is the MAXIMUM amount of doxorubicin that could be cleaved by FAP since some may be excreted uncleaved just as some straight doxorubicin may be excreted without acting on cells. The PK data from the trials, Phase 1a and now also Phase 2, will provide that information for both AVA6000 and straight doxorubicin. It is certainly absolutely true that AVA6000 targets and concentrates doxorubicin in the TME and will be delivering massive doses there.